REferences
- Yokota S, Mori M, Imagawa T, Takei S, Murata T, Tomiita M, et al. Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and non-pediatric rheumatologists (2007). Mod Rheumatol. 2007;17: 353–63.
- van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, et al. Efficacy and safety of adalimumab as mono-therapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508–16.
- van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136–46.
- Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–38.
- Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18:341–50.
- Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–20.
- Miyasaka N. The CHANGE Study Investigator. Clinical inves-tigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evalua-tion: the CHANGE study. Mod Rheumatol. 2008;18:252–62.
- Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab M04-688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Der-matol. 2010;37: 299–310.
- Cassidy JT. Chronic arthritis, poly arthritis, oligoarthritis, sys-temic arthritis. In: Cassidy JT, Petty RE, Laxer RM, Linsley CB, editors. Textbook of Pediatric Rheumatology. 5th ed. ed. Phila-delphia: Elsevier Saunders; 2005. p. 206–303.
- Harrington J. Developmental issues in adolescence and the impact of rheumatic disease. In: Isenberg DA, Miller JJ, editors. Adolescent Rheumatology. London: Martin Dunitz; 2000. p. 21–34.
- Grom AA, Murray KJ, Luyrink L, Emery H, Passo MH, Glass DN, et al. Pattern of expression of tumor necrosis factor z tumor necrosis factor /3, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy. Arthritis Rheum. 1996;39:1703–10.
- Eberhard BA, Laxer RM, Andersson U, Silverman ED. Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol. 1994;96:260–6.
- Fink CW. Proposal for the development of classification criteria for the idiopathic arthritides of childhood. J Rheumatol. 1995;22:1566–9.
- Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and valida-tion in a prospective longitudinal study of patients with rheu-matoid arthritis. Arthritis Rheum. 1995;38:44–8.
- Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.